Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colorectal Neoplasm Clear all
Completed Phase 2 Interventional

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01326000
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFIRI, RO5083945, cetuximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Encinitas, California • Highland, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 22, 2026, 1:13 PM EDT
Recruiting Phase 3 Interventional

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

NCT07702032
View directory record Official record
Conditions
Left-sided Colorectal Cancer
Interventions
Petosemtamab, Cetuximab, FOLFIRI, mFOLFOX6
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Savannah, Georgia • Warner Robins, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer

NCT01656044
View directory record Official record
Conditions
Colon Cancer, Pancreatic Cancer, Perioperative/Postoperative Complications, Primary Peritoneal Cavity Cancer, Rectal Cancer
Interventions
wound care management
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cancer Communication Within Hispanic Social Networks

NCT04444232
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Media Intervention, Survey Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 22, 2026, 1:13 PM EDT
Withdrawn Not applicable Interventional

Hand Assisted Versus "Pure" Laparoscopic Assisted Proctectomy for Rectal Cancer

NCT00651677
View directory record Official record
Conditions
Rectal Cancer
Interventions
HAL proctectomy, "straight" laparoscopic proctectomy, Hand-assisted laparoscopic proctectomy, SL Proctectomy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2 Interventional

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

NCT00055419
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2010 · Synced Sep 22, 2026, 1:13 PM EDT
Recruiting Phase 1 Interventional

Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

NCT06225011
View directory record Official record
Conditions
Colorectal Adenocarcinoma
Interventions
Fluoxetine
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Terminated Phase 2 Interventional

ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer

NCT00385021
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
5-Fluorouracil, leucovorin, oxaliplatin, avastin
Drug
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
18 Years to 86 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Sep 22, 2026, 1:13 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

NCT04136002
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
44,467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
271
States / cities
Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

NCT01511653
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
13,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
7
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 22, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

NCT06937177
View directory record Official record
Conditions
Cancer Weight Loss
Interventions
TCMCB07, Placebo
Drug
Lead sponsor
Endevica Bio
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Withdrawn Phase 2 Interventional

Anti-PD-1 +/- RT for MSI-H Solid Tumors

NCT04001101
View directory record Official record
Conditions
Microsatellite Instability High, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
RT and Anti-PD-1, Anti-PD-1
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 22, 2026, 1:13 PM EDT
Recruiting No phase listed Observational

Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases

NCT05248581
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Liver transplantation
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Elironrasib, Daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Duarte, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Terminated Phase 2 Interventional

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

NCT01832857
View directory record Official record
Conditions
Cancer
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

NCT01312857
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
panitumumab, Randomization to No Panitumumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

NCT05104567
View directory record Official record
Conditions
Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
Interventions
THOR-707, Pembrolizumab, Cetuximab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Duarte, California • Orlando, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 22, 2026, 1:13 PM EDT
Withdrawn Phase 2 Interventional

Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma

NCT00725400
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Cetuximab and Radiation Therapy, Surgery and Radiation Therapy
Other · Procedure
Lead sponsor
American Scitech International
Other
Eligibility
40 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational

Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer

NCT00950144
View directory record Official record
Conditions
Colorectal Cancer, Depression, Fatigue, Liver Cancer, Pain, Pancreatic Cancer
Interventions
medical chart review, questionnaire administration, study of socioeconomic and demographic variables, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants

NCT00478309
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease
Interventions
counseling intervention, educational intervention
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
50 Years and older
Enrollment
697 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer

NCT00695201
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Floxuridine, Oxaliplatin, CPT-11
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 22, 2026, 1:13 PM EDT